2025年2月到2026年2月，A股市场迎来了一轮强劲的上涨行情。 上证指数从3200点左右起步，一路攀升至4000点上方，累计涨幅达到25.58%。 深证成指的 表现更加抢眼，从11000点附近涨到15000点以上，涨幅高达38.84%。 创业板指更是从2200点飙升至3500点，涨幅接近59%。 科创50指数也不甘示弱，涨幅超过64%。 全市场5484只股票中，有4788只实现了上涨，上涨比例超过87%。 其中869只股票价格翻倍，更有100多只股票涨幅在2倍到20倍之间。 投资者们沉浸在赚钱的喜悦中，社交媒体上到处是晒收益的截图，券商营业部里开户排队的人群络绎不绝。 就在这一片欢腾的市场氛围中，却有700多只股票逆市下跌。 其中跌幅最大的10只股票，股价几乎全部腰斩，跌幅最小的也有42%。 这些股票所属行业各不 相同，有通信服务、环保设备、生物制品、零售、建筑装饰、食品加工、文化传媒、光伏设备、光学光电子等多个领域。 华星创业的股价从年内高点15.88元一路下跌到6.18元，区间跌幅达到63%。 这家通信服务行业的公司，曾经在2023年初达到20.95元的高点，如今股价已经跌回到三年前的水平。 公司20 ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-010 北京康乐卫士生物技术股份有限公司 股权质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、股权质押概述 （一）基本情况 公司股东天狼星控股集团有限公司质押 8,000,000 股，占公司总股本 2.85%。 在本次质押的股份中，8,000,000 股为有限售条件股份，0 股为无限售条件股份。 质押期限为 2026 年 2 月 9 日起至业务结清止。质押股份用于融资性质押，质押 权人为湖北中财典当有限责任公司，质押权人与质押股东不存在关联关系。质押 股份已在中国结算办理质押登记。 公司股东北京江林威华生物技术有限公司质押 4,440,000 股，占公司总股本 1.58%。在本次质押的股份中，4,440,000 股为有限售条件股份，0 股为无限售条 件股份。质押期限为 2026 年 2 月 12 日起至业务结清止。质押股份用于融资性质 押，质押权人为海口江源壹号企业管理中心（有限合伙），质押权人与质押股东 存在关联关系。质押 ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-012 北京康乐卫士生物技术股份有限公司 关于三价和九价 HPV 疫苗临床试验暂停的公告 公司九价 HPV 疫苗（女性适应症）Ⅲ期临床试验于 2025 年 2 月达到临床方 案规定的主要终点病毒学终点（PI12）收集要求并形成期中分析报告，目前本项 目正在开展 48 至 54 月访视，并处于持续积累临床方案次要终点 CIN2+病例的 过程中。公司九价 HPV 疫苗（女性适应症）已完成临床方案主要终点的病例收 集工作，但如果临床试验及桥接试验长时间未恢复正常，将可能对本项目次要终 点的病例收集、疫苗阔龄和上市申请工作造成一定的不良影响。 三、风险提示 由于疫苗研发本身具有高风险、高投入、长周期等特点，从临床前研究、临 床试验到产品申报上市的过程时间长、环节多，存在一定的不确定性。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、临床试验暂停的原因 近日，北京康乐卫士生物技术股份有限公司（以下简称"公司"）收到湖南 省疾病预防控制中心发送的 ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-011 北京康乐卫士生物技术股份有限公司 解除股权质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 解除股权质押情况 （一） 本次解除股权质押基本情况 公司接到股东天狼星控股集团有限公司的通知，股东天狼星控股集团有限公 司本次解除股份质押8,000,000股，占其所持股份13.24%，占公司总股本2.85%。 本次解质的股份中，8,000,000 股为有限售条件股份，0 股为无限售条件股份， 解质的股份已在中国结算办理相关手续，解除日期为 2026 年 2 月 11 日。上述股 份于 2025 年 9 月 30 日被质押，质押权人为北京市富安小额贷款有限公司。 （二） 剩余被质押股权的情况 截至公告披露日，公司股东天狼星控股集团有限公司剩余被质押股份为 27,455,697 股，占其所持股份的 45.43%，占公司总股本的 9.77%。剩余被质押 股份中，27,455,697 股为有限售条件股份，0 股为无限售条件股份。 二 ...

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies [32]. Core Insights - The North Exchange A-share trading volume reached 16.95 billion yuan on February 11, a decrease of 2.38 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1525.49, down 0.44% [8][16]. - Among the 293 companies listed on the North Exchange, 73 saw an increase in stock prices, 9 remained flat, and 211 experienced declines [18]. - The top five gainers included Minshida (8.4%), Gebijia (8.0%), Lingge Technology (7.6%), Kebaier (6.9%), and Jinhua New Materials (6.5%) [18]. - The top five decliners were Kaide Quartz (-7.4%), Optoelectronics (-6.1%), Liujin Technology (-5.7%), Hengtong Light (-5.2%), and Kangle Guardian (-4.8%) [18]. Summary by Sections Market Review - On February 11, the North Exchange A-share trading volume was 16.95 billion yuan, a decrease of 2.38 billion yuan from the previous day, with the North Exchange 50 Index closing at 1525.49, down 0.44% [8][16]. - The North Exchange Specialized and New Index closed at 2552.04, up 0.08% [8]. Important News - The State Council aims to establish a unified national electricity market system by 2035, with market-based electricity transactions accounting for about 70% of total electricity consumption by 2030 [21]. - The national standard for vehicle solid-state batteries is expected to be released in July 2026 [22]. Key Company Announcements - Ximic Technology reported a revenue of 96,079,621.14 yuan for 2025, a decrease of 23.05% year-on-year, with a net profit of 4,670,419.54 yuan, down 76.74% [23]. - Lintai New Materials plans to raise up to 380 million yuan through a private placement, with funds allocated for projects related to automotive components and high-end equipment manufacturing [24].

证券代码：920575 证券简称：康乐卫士 公告编号：2026-009 北京康乐卫士生物技术股份有限公司 关于子公司申请银行授信暨公司及关联方提供担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、担保情况概述 （一）担保基本情况 北京康乐卫士生物技术股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日召开第五届董事会 2025 年第一次独立董事专门会议、第五届董事会第五次 会议、第五届监事会第五次会议，审议通过《关于子公司申请银行授信暨公司及 关联方提供担保的议案》，同意公司子公司康乐卫士（昆明）生物技术有限公司 （以下简称"昆明康乐"）向华夏银行股份有限公司昆明圆通支行申请授信额度 6,000 万元（其中短期流动资金贷款额度 3,000 万元），业务品种包括短期流动资 金贷款、银行承兑汇票、贸易融资等，授信期限 1 年，用于采购生产所需原材料 及其他日常营运支出，担保方式为：授信净额 3,000 万元由公司及公司实际控制 人陶涛先生提供连带责任保证担保。具体内容详见公司于 ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-008 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度净利润为负值 单位：万元 北京康乐卫士生物技术股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、本期业绩预告情况 | 项目 | | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | --- | | 归属于上市 | 公司 | -33,967.20～-27,791.35 | -35,660.62 | 4.75%～22.07% | | 股东的净利润 | | | | | 二、本期业绩重大变化的主要原因 公司自成立以来持续进行疫苗产品研发，截至 2025 年 12 月 3 ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]